Cancer cells impair monocyte-mediated T cell stimulation to evade immunity.
Saved in:
| Title: | Cancer cells impair monocyte-mediated T cell stimulation to evade immunity. |
|---|---|
| Authors: | Elewaut A; Research Institute of Molecular Pathology (IMP), Vienna BioCenter (VBC), Vienna, Austria.; Vienna BioCenter, Doctoral School of the University of Vienna and Medical University of Vienna, Vienna, Austria., Estivill G; Research Institute of Molecular Pathology (IMP), Vienna BioCenter (VBC), Vienna, Austria.; Vienna BioCenter, Doctoral School of the University of Vienna and Medical University of Vienna, Vienna, Austria., Bayerl F; Institute of Molecular Immunology, School of Medicine and Health, Technical University of Munich (TUM), Munich, Germany., Castillon L; Translational Cancer Medicine Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland., Novatchkova M; Research Institute of Molecular Pathology (IMP), Vienna BioCenter (VBC), Vienna, Austria., Pottendorfer E; Research Institute of Molecular Pathology (IMP), Vienna BioCenter (VBC), Vienna, Austria.; Vienna BioCenter, Doctoral School of the University of Vienna and Medical University of Vienna, Vienna, Austria., Hoffmann-Haas L; Research Institute of Molecular Pathology (IMP), Vienna BioCenter (VBC), Vienna, Austria., Schönlein M; Research Institute of Molecular Pathology (IMP), Vienna BioCenter (VBC), Vienna, Austria., Nguyen TV; Research Institute of Molecular Pathology (IMP), Vienna BioCenter (VBC), Vienna, Austria., Lauss M; Lund University Cancer Center, Division of Oncology, Lund University, Lund, Sweden., Andreatta F; Research Institute of Molecular Pathology (IMP), Vienna BioCenter (VBC), Vienna, Austria., Vulin M; Research Institute of Molecular Pathology (IMP), Vienna BioCenter (VBC), Vienna, Austria., Krecioch I; Research Institute of Molecular Pathology (IMP), Vienna BioCenter (VBC), Vienna, Austria., Bayerl J; Research Institute of Molecular Pathology (IMP), Vienna BioCenter (VBC), Vienna, Austria.; Vienna BioCenter, Doctoral School of the University of Vienna and Medical University of Vienna, Vienna, Austria., Pedde AM; Institute of Molecular Immunology, School of Medicine and Health, Technical University of Munich (TUM), Munich, Germany., Fabre N; Research Institute of Molecular Pathology (IMP), Vienna BioCenter (VBC), Vienna, Austria., Holstein F; Research Institute of Molecular Pathology (IMP), Vienna BioCenter (VBC), Vienna, Austria.; Vienna BioCenter, Doctoral School of the University of Vienna and Medical University of Vienna, Vienna, Austria., Cronin SM; Research Institute of Molecular Pathology (IMP), Vienna BioCenter (VBC), Vienna, Austria.; Vienna BioCenter, Doctoral School of the University of Vienna and Medical University of Vienna, Vienna, Austria., Rieser S; Research Institute of Molecular Pathology (IMP), Vienna BioCenter (VBC), Vienna, Austria., Laniti DD; Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne (UNIL), Lausanne, Switzerland.; Department of Oncology, University Hospital of Lausanne (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland.; Agora Research Center, Lausanne, Switzerland., Barras D; Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne (UNIL), Lausanne, Switzerland.; Department of Oncology, University Hospital of Lausanne (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland.; Agora Research Center, Lausanne, Switzerland., Coukos G; Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne (UNIL), Lausanne, Switzerland.; Department of Oncology, University Hospital of Lausanne (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland.; Agora Research Center, Lausanne, Switzerland., Quek C; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.; Charles Perkins Centre, The University of Sydney, Sydney, New South Wales, Australia.; Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia., Bai X; Melanoma Institute Australia, The University of Sydney, Sydney, New South Wales, Australia.; Charles Perkins Centre, The University of Sydney, Sydney, New South Wales, Australia.; Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia., Muñoz I Ordoño M; Research Institute of Molecular Pathology (IMP), Vienna BioCenter (VBC), Vienna, Austria., Wiesner T; Department of Dermatology, Medical University of Vienna, Vienna, Austria., Zuber J; Research Institute of Molecular Pathology (IMP), Vienna BioCenter (VBC), Vienna, Austria., Jönsson G; Lund University Cancer Center, Division of Oncology, Lund University, Lund, Sweden., Böttcher JP; Institute of Molecular Immunology, School of Medicine and Health, Technical University of Munich (TUM), Munich, Germany., Vanharanta S; Translational Cancer Medicine Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.; Department of Biochemistry and Developmental Biology, Faculty of Medicine, University of Helsinki, Helsinki, Finland., Obenauf AC; Research Institute of Molecular Pathology (IMP), Vienna BioCenter (VBC), Vienna, Austria. anna.obenauf@imp.ac.at. |
| Source: | Nature [Nature] 2025 Jan; Vol. 637 (8046), pp. 716-725. Date of Electronic Publication: 2024 Nov 27. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Nature Publishing Group Country of Publication: England NLM ID: 0410462 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-4687 (Electronic) Linking ISSN: 00280836 NLM ISO Abbreviation: Nature Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
